CD274 and non-small cell lung carcinoma: Furthermore, clinical trials have demonstrated remarkable efficacy of combined nivolumab and ipilimumab therapy in melanoma (ORR: ~60%) (194, 341), although combined durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) in NSCLC was not successful in a recent phase 3 study (Table 3).